Tg Therapeutics Inc SEC Filings

TG Therapeutics reported Q3 2025 results highlighted by strong BRIUMVI sales and a large tax benefit. Total revenue was $161.7M, driven by product revenue of $159.3M. Operating income reached $29.4M, and net income was $390.9M, reflecting an income tax benefit of $365.0M. Diluted EPS was $2.43.

For the first nine months, total revenue was $423.7M, including $417.8M of product revenue, with $6.4M from BRIUMVI sales to Neuraxpharm. Accounts receivable were $265.4M and inventories $147.0M as of Sep 30, 2025. Cash, cash equivalents and investment securities totaled $178.3M, while loan payable (non‑current) was $245.3M.

The company completed its $100M share repurchase program, buying 2,782,545 shares for $78.2M in Q3, and authorized a new $100M program. There were 158,759,451 common shares outstanding as of Oct 31, 2025.

TG Therapeutics (TGTX) notice of proposed sale reports an insider intends to sell 20,852 common shares through Fidelity Brokerage Services on NASDAQ with an aggregate market value of $672,232.59. These shares represent approximately 0.013% of the reported 158,665,613 shares outstanding and were acquired on 06/22/2023 by restricted stock vesting as compensation.

The filing lists no securities sold in the past three months and specifies the proposed sale date as 09/11/2025. The filer affirms they are not aware of any undisclosed material adverse information about the issuer. This is a routine Rule 144 disclosure showing a planned disposition of vested equity awarded as compensation.

TG Therapeutics, Inc. filed a Form S-8 registration statement on August 8, 2025 to register securities under the TG Therapeutics, Inc. 2022 Incentive Plan. The filing incorporates by reference the company’s Annual Report for the fiscal year ended December 31, 2024 (filed March 3, 2025) and subsequent Exchange Act reports, and lists exhibits including the 2022 Incentive Plan and two amendments, legal opinion of DLA Piper LLP and KPMG consent.

The filing indicates the company is a large accelerated filer, names Sean Power as agent for service, and describes charter and bylaw provisions limiting director liability (excluding liabilities under federal securities laws). Item 4 is marked Not applicable.

TG Therapeutics, Inc. (TGTX) filed a Form S-3 shelf registration as a well-known seasoned issuer on August 8, 2025, providing a framework to offer common stock, preferred stock, warrants, debt securities and units from time to time. The prospectus states proceeds will be used for general corporate purposes and that specific terms will be supplied in prospectus supplements. The company describes itself as a commercial-stage biopharmaceutical firm with FDA approval of BRIUMVI (ublituximab-xiiy) for relapsing forms of multiple sclerosis and parallel approvals in the EU and the UK.

The prospectus discloses 158,665,613 shares outstanding as of August 5, 2025 and approximately 199 holders of record, authorized common stock of 190,000,000 shares, and authorized preferred stock of 10,000,000 shares (none outstanding). The registrant notes the Nasdaq symbol "TGTX" and a closing price of $27.70 per share on August 6, 2025. The document incorporates prior reports including the 2024 Form 10-K and 2025 Form 10-Q filings and highlights extensive forward-looking risk factors that investors should review.

TG Therapeutics reported strong year-over-year commercial progress driven by BRIUMVI sales and improved profitability. For the six months ended June 30, 2025 the company recognized $262.0 million of total revenue, primarily product revenue from U.S. BRIUMVI sales, compared with $136.9 million in the prior-year period. GAAP net income was $33.2 million for the six months and $28.2 million for the quarter, reversing prior-year losses.

The balance sheet shows current assets of $663.96 million including cash, cash equivalents and investment securities the company states as $278.9 million available with management anticipating liquidity for more than twelve months. Working capital increased: accounts receivable rose to $231.5 million and inventory to $155.2 million. The company has a secured term loan with a carrying amount of $245.0 million (non-current) and an accumulated deficit of approximately $1.5 billion. Results reflect ongoing commercialization of BRIUMVI and related license revenue from ex-U.S. partner Neuraxpharm.